A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Bing Chen, M.D.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Principal Investigator - Lijuan Chen, M.D.
The First Affiliated Hospital with Nanjing Medical University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Anhui Provincial Cancer Hospital
Hefei, Anhui, China
- the First People'S Hospital of Changzhou
Changzhou, Jiangsu, China
- Jiangsu Province Hospital
Nanjing, Jiangsu, China
- Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2022
- Primary completion
- 30 Apr 2024
- Completion
- 30 Apr 2039
- Last update posted
- 6 Jan 2022
- Registered enrollment
- 20
- Registry id
- NCT05181501
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.